The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption
暂无分享,去创建一个
Sundeep Khosla | D. Lacey | B. Riggs | S. Khosla | W. J. Boyle | C. Dunstan | Lorenz C Hofbauer | Lorenz C. Hofbauer | Colin R. Dunstan | David L. Lacey | William J. Boyle | B. Lawrence Riggs | Lorenz C. Hofbauer | L. Hofbauer
[1] B. Aggarwal,et al. Characterization of the Intracellular Domain of Receptor Activator of NF-κB (RANK) , 1998, The Journal of Biological Chemistry.
[2] S. Reddy,et al. Control of osteoclast differentiation. , 1998, Critical reviews in eukaryotic gene expression.
[3] R. Kitazawa,et al. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. , 1994, The Journal of clinical investigation.
[4] G. Mundy,et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β , 1996, Nature Medicine.
[5] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[6] S. Mochizuki,et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.
[7] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[8] A. Di Giorgio,et al. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. , 1998, The Journal of clinical endocrinology and metabolism.
[9] B. Riggs,et al. Osteoclasts and transforming growth factor-beta: estrogen-mediated isoform-specific regulation of production. , 1996, Endocrinology.
[10] E. Barengolts,et al. Osteoporosis and Coronary Atherosclerosis in Asymptomatic Postmenopausal Women , 1998, Calcified Tissue International.
[11] B. Riggs,et al. Modulation of Transforming Growth Factor-β Production in Normal Human Osteoblast-Like Cells by 17β-Estradiol and Parathyroid Hormone , 1991 .
[12] Roodman Gd. Advances in bone biology : The osteoclast , 1996 .
[13] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[14] D. Dempster. Perspectives bone histomorphometry in glucocorticoid‐induced osteoporosis , 1989 .
[15] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[16] L. Hood,et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. , 1998, Journal of immunology.
[17] C. Thompson,et al. Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death. , 1998, Genes & development.
[18] M. Kumegawa,et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. , 1998, Biochemical and biophysical research communications.
[19] H. Broxmeyer,et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.
[20] C. Ohlsson,et al. Tumor Necrosis Factor-α and -β Upregulate the Levels of Osteoprotegerin mRNA in Human Osteosarcoma MG-63 Cells , 1998 .
[21] N. Nagata,et al. Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells , 1998 .
[22] R. Kimble,et al. The Functional Block of TNF but Not of IL‐6 Prevents Bone Loss in Ovariectomized Mice , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[23] Roberto Pacifici,et al. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] B. Riggs,et al. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. , 1999, Molecular endocrinology.
[25] S. Morony,et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.
[26] Brian R. Wong,et al. TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.
[27] C. Ohlsson,et al. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. , 1998, Biochemical and biophysical research communications.
[28] E. Wagner,et al. Bone and haematopoietic defects in mice lacking c-fos , 1992, Nature.
[29] B. Riggs,et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. , 1998, Biochemical and biophysical research communications.
[30] K. Miyake,et al. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. , 1998, Biochemical and biophysical research communications.
[31] R. Jilka,et al. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. , 1998, Bone.
[32] H. Kawaguchi,et al. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae. , 1995, The Journal of clinical investigation.
[33] D. Lacey,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in , 2022 .
[34] G. Gronowicz,et al. Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] N. Udagawa,et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. , 1998, Biochemical and biophysical research communications.
[36] H. Genant,et al. A Preliminary Evaluation of the Lunar Expert‐XL for Bone Densitometry and Vertebral Morphometry , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[37] P. Young,et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. , 1997, Gene.
[38] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[39] C. Dinarello,et al. Biologic basis for interleukin-1 in disease. , 1996, Blood.
[40] E. Jimi,et al. Regulation of Osteoclast Function , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[41] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[42] B. Spiegelman,et al. Pleiotropic effects of a null mutation in the c-fos proto-oncogene , 1992, Cell.
[43] P. Kelly,et al. Quantitative microradiographic study of bone remodeling in Cushing's syndrome. , 1966, Metabolism: clinical and experimental.
[44] D. Lacey,et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.
[45] R. Steinman,et al. The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor* , 1998, The Journal of Biological Chemistry.
[46] S. Ikuyama,et al. Glucocorticoid-induced osteoporosis: pathogenesis and management , 2000, Journal of Bone and Mineral Metabolism.
[47] T. Komori,et al. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). , 1998, Biochemical and biophysical research communications.
[48] John C. Lee,et al. Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.
[49] T. Martin,et al. Modulation of osteoclast differentiation. , 1992, Endocrine reviews.
[50] M. Goto,et al. Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor* , 1998, The Journal of Biological Chemistry.
[51] G. Cheng,et al. An Intact Zinc Ring Finger Is Required for Tumor Necrosis Factor Receptor-associated Factor-mediated Nuclear Factor-κB Activation but Is Dispensable for c-Jun N-terminal Kinase Signaling* , 1998, The Journal of Biological Chemistry.
[52] U. Lerner,et al. Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[53] B. Aggarwal,et al. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. , 1999, The Journal of biological chemistry.
[54] K. Ikeda,et al. Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[55] H. Yasuda,et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.
[56] F. Ross,et al. Estrogen Deficiency Increases the Ability of Stromal Cells to Support Murine Osteoclastogenesis via an Interleukin-1and Tumor Necrosis Factor-mediated Stimulation of Macrophage Colony-stimulating Factor Production* , 1996, The Journal of Biological Chemistry.
[57] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[58] B. Riggs,et al. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[59] S. Mochizuki,et al. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. , 1998, Endocrinology.
[60] J. Caamaño,et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2 , 1997, Nature Medicine.
[61] Li Sun,et al. Mode of Action of Interleukin-6 on Mature Osteoclasts. Novel Interactions with Extracellular Ca2+ Sensing in the Regulation of Osteoclastic Bone Resorption , 1998, The Journal of cell biology.
[62] B. Aggarwal,et al. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. , 1998, The Journal of biological chemistry.
[63] R. Kimble,et al. Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. , 1993, The Journal of clinical endocrinology and metabolism.
[64] N. Udagawa,et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. , 1998, Biochemical and biophysical research communications.
[65] G. Roodman,et al. Advances in bone biology: the osteoclast. , 1996, Endocrine reviews.
[66] S. Mochizuki,et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. , 1998, Biochemical and biophysical research communications.
[67] D. Lacey,et al. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .
[68] W. Dougall,et al. The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.
[69] T. Suda. Modulation of osteoclast differentiation [published erratum appears in Endocr Rev 1992 May;13(2):191] , 1992 .
[70] T. Martin,et al. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. , 1998, Endocrinology.
[71] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[72] I. Reid. Glucocorticoid osteoporosis--mechanisms and management. , 1997, European journal of endocrinology.
[73] H. Yasuda,et al. Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. , 1998, Gene.
[74] T. Komori,et al. Excessive extramedullary hematopoiesis in Cbfa1-deficient mice with a congenital lack of bone marrow. , 1999, Biochemical and biophysical research communications.
[75] S. Mochizuki,et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.
[76] T. Steinberg,et al. Impaired intramembranous bone formation in connexin43 null mice , 1998 .
[77] K. Chihara,et al. Dexamethasone Stimulates Osteoclast‐like Cell Formation by Directly Acting on Hemopoietic Blast Cells and Enhances Osteoclast‐like Cell Formation Stimulated by Parathyroid Hormone and Prostaglandin E2 , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[78] B. L. Riggs,et al. A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging Men , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[79] C. Ohlsson,et al. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. , 1998, The Journal of endocrinology.
[80] S. Mochizuki,et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. , 1998, Bone.
[81] K. Ikeda,et al. Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells* , 1998, The Journal of Biological Chemistry.
[82] L. Lum,et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. , 1999, The Journal of biological chemistry.
[83] K. Sjögren,et al. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. , 1998, Biochemical and biophysical research communications.
[84] S. Mochizuki,et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. , 1998, Biochemical and biophysical research communications.
[85] L. Lum,et al. Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, The Journal of Biological Chemistry.
[86] B. Kwon,et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[87] A. Parfitt,et al. Theoretical perspective: A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates , 1996 .
[88] K Yano,et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.
[89] D. Lacey,et al. The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.
[90] C. O’Brien,et al. STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone* , 1999, The Journal of Biological Chemistry.
[91] G. Roodman,et al. Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[92] G. Mundy,et al. Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. , 1988, The Journal of clinical investigation.
[93] R. Jilka,et al. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.
[94] E. Hammond,et al. The Cell-surface Form of Colony-stimulating Factor-1 Is Regulated by Osteotropic Agents and Supports Formation of Multinucleated Osteoclast-like Cells* , 1998, The Journal of Biological Chemistry.